Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006.
Long GV, Arance A, Mortier L, Lorigan P, Blank C, Mohr P, Schachter J, Grob JJ, Lotem M, Middleton MR, Neyns B, Steven N, Ribas A, Walpole E, Carlino MS, Lebbe C, Sznol M, Jensen E, Leiby MA, Ibrahim N, Robert C.
Long GV, et al. Among authors: middleton mr.
Ann Oncol. 2022 Feb;33(2):204-215. doi: 10.1016/j.annonc.2021.10.010. Epub 2021 Oct 25.
Ann Oncol. 2022.
PMID: 34710571
Free article.
Clinical Trial.